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Introduction: This research was conducted on the topic of dual diagnosis (DD) patients with co-
occurring schizophrenia (SZ) and substance use disorder (SUD). The research question posed for 
this topic: among patients with a DD of SZ and SUD what current treatments offer optimal 
outcomes?  
Methods: The research for this paper was predominantly a literature review. Forty-five sources 
were utilized in its construction. The majority of sources were peer-reviewed studies obtained 
from an online service via the Lindell Library at Augsburg University. Three textbooks were 
utilized. One expert interview was conducted. 
Results: Three key findings within the research identified first, SUD rates were shown to be 
higher among patients with SZ than the general population (47-70% vs. 6%). The second finding 
suggests that Long-acting injectable (LAI) medications have shown promise in offering optimal 
outcomes due to fewer opportunities for missed doses. Third, according to a U.S. prison study 
and two leading mental health organizations, 26.1% and 3% of inmates had documented SUDs 
or SZ diagnosis respectively compared to 6% and 0.25-0.64% in the general population.  
Discussion: In this essay I will discuss the issue of this patient population disproportionately 
overlapping with the CJS and the demand for policy change and societal accountability. More 
resources will need to be dedicated to this patient population in order to move towards optimal 
outcomes. Patients with SZ and SUD have complex needs and require an interdisciplinarian 






 Schizophrenia (SZ) is a form of severe and persistent mental illness (SPMI) that affects 
roughly 0.5-1% of the global population and more than 2.4 million adults in the United States.1 
The economic burden of SZ was estimated at $62.7 billion in the U.S. in 2002 accounting for 
1.5-3% of the total national healthcare expenditures.1 Substance use disorder (SUD) is a more 
recent diagnostic classification of chemical dependency outlined in the Diagnostic and Statistical 
Manual of Mental Disorders, 5th edition (DSM-V). Roughly 6% of adults aged 18 and older in 
the U.S. in 2017 had an SUD.2 Dual diagnosis (DD) is a term describing patients with co-
occurring psychiatric and SUD diagnoses. One textbook written for clinicians treating patients 
with DDs quotes a prevalence rate for co-occurring SUDs among individuals with SZ ranging 
from 47-70%.3 Individuals with SZ have a much higher prevalence rate for co-occurring SUDs 
in their lifetimes than the general population. SZ patients with co-occurring SUD have 
historically lacked access to adequate healthcare at a level disproportionate to individuals with 
either SZ or SUD on their own.4 This DD population is also overrepresented in U.S. jails and 
prisons. 
 SZ is characterized by psychosis which is described as, “a fundamental derangement of 
the mind characterized by a loss of contact with reality”.1 SZ is the most common manifestation 
of psychosis and the most debilitating psychotic diagnosis within the schizophrenia spectrum 
disorders (SSD). A SZ diagnosis must include at least two of the following symptoms: 
hallucinations, disorganized speech, delusions, negative symptoms, and grossly disorganized or 
catatonic behavior.1 Additionally, the disturbance must be present for at least 6 months, there 
must be significant deficiencies in major areas of function (work, self-care, interpersonal 
6 
 
relations), symptoms must not be attributable to another psychiatric disorder, and symptoms 
must not be attributable to another medical condition or substance.1 
 Hallucinations are strong subjective perceptions of external objects or events when no 
such stimulus or situation is present.1 Auditory hallucinations are the most common form of 
hallucination (opposed to tactile or visual) and are experienced as voices distinct from an 
individual’s own thoughts. Auditory hallucinations often have a negative or derogatory tone 
experienced by the patient. Delusions are fixed false beliefs that are held with strong conviction 
despite existing evidence to the contrary.1 Delusions manifest in the form of themes such as 
grandiosity, persecutory, erotomanic, or referential. Disorganized thoughts are a derailment or 
loose association of thoughts as demonstrated by an individual switching between unrelated 
topics as if they were closely associated topics.1 The most extreme form of disorganized thought 
is termed ‘word salad’ which is described as speech so disorganized it is nearly completely 
incomprehensible.1 Negative symptoms consist of decreased motivation (avolition), the inability 
to experience joy or pleasure (anhedonia), a diminished emotional expression, a decreased 
interest in social interaction (asociality), and decreased speech (alogia).1 Catatonia is a 
psychomotor disturbance that consists of either decreased motor activity, interaction, or 
excessive odd motor activity.5 
 The research conducted for this paper focused on optimal treatments for DD patients with 
co-occurring SZ and SUD. The general outline of the contents of this paper is as follows: a 
literature review of the overlap between SZ and SUD, a literature review of evidence-based 
treatments used in this DD population, a literature review of the unique role that the criminal 
justice system plays in this patient population and its relevance to treatments and outcomes, a 
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description of the methods used to conduct research, a discussion analyzing the literature 
reviewed, and a conclusion of the investigated research question. 
Part 1 Literature Review: Overlap Between SZ and SUD 
A great deal of research has been conducted in recent decades regarding the co-
occurrence of SZ and SUD diagnoses. Patients with a SZ diagnosis are very likely to carry an 
additional SUD diagnosis. Understanding this sub-population and why there is such a significant 
co-occurrence rate is important for multiple reasons: this patient population has historically been 
undertreated, these patients have unique needs, and this patient population has historically had 
complicated treatment outcomes.  
Overlap  
Various studies report different prevalence levels of SUDs among SZ patients. 
Epidemiological studies have shown that among patients with SZ the prevalence rate of SUDs 
(excluding tobacco) is 47%.6 While tobacco dependence is a significant issue among persons 
with SZ, many studies on this topic exclude tobacco from their results owing to the fact that 
tobacco use disorder is a separate diagnosis in the DSM-V; additionally, this population often 
has a tobacco use rate that approaches 90%. A systematic review of 26 articles published from 
1990-2015 found that between 18.5-61.5% of people with SZ develop a SUD during their lives.7 
According to the ACCESS II study, out of 187 SZ patients in Germany, 126 (67.4%) had a 
comorbid SUD diagnosis.8 A different study conducted in South Africa with a sample of 1,420 
patients with SZ demonstrated that SUDs were present among 47.8% of the participants.9 A 
Danish study using patients from nation-wide Danish registers between 1968-2013 specifically 
analyzed the timeline of events pertaining to SUDs diagnosed in SZ patients later in life. They 
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found that of 14,007 patients diagnosed with SZ between 1968-2015, 20.6%10 went on to 
develop an SUD at some point in their lives (see Table 1). It is worth reiterating here that this 
study observed that 20.6% of 14,007 patients diagnosed with SZ went on to develop an SUD 
later in life. This statistic does not capture those diagnosed with SUD prior to or at the time of 
their SZ diagnosis. So, 20.6% of patients with SZ from Danish registers between 1968-2015 
should not be compared with the above noted co-occurring prevalence rates. 
Most Common Substances 
Both legal and illicit substances are found to have varying degrees of use among SZ 
patients with concurrent SUDs. Of the 126 SZ patients in the ACCESS II study who were 
observed to have an SUD, 60.3% reported using one substance, 27.8% reported using two 
substances, and 15% reported using more than two substances. The most commonly used 
substances were alcohol (abuse: 33.3%, dependence: 38.9%) and cannabis (abuse: 11.9%, 
dependence: 38.9%).8 According to the previously mentioned systematic review of 26 published 
studies on persons with SZ and SUDs 70% of persons with SZ (PWS) are nicotine dependent, 
20-60% use alcohol, 16-59% use cannabis, and up to 54% use khat which is a stimulant-like 
evergreen plant regularly used by people in the Horn of Africa.7 The Danish study which 
identified 14,007 patients with schizophrenia showed the most common types of substances used 
were as follows: alcohol (49.5%), cannabis (16.3%), opioids (7.7%), sedatives (5.8%), stimulants 
(5.3%), cocaine (3.2%), other (2.9%), and hallucinogens (0.5%).10 The South Africa study 
showed that of the 678 SZ subjects with SUDs the most commonly abused substances were 
cannabis (39.6%), alcohol (20.5%), methaqualone (6.2%), methamphetamine (4.8%), and other 
drugs including cocaine, ecstasy, opioids (0.6%).9 Although, the studies reviewed for this 
research show different prevalence rates for most common substances used by this population, 
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there is consensus that alcohol and cannabis are the most frequently used substances among this 
patient population.  
Outcomes 
SUD in patients with SZ is often associated with difficulties in treatment adherence and 
frequently worse outcomes when compared to treatment outcomes for SZ patients without SUDs. 
A study with two cohorts of more than 45,000 SZ patients in Finland and Sweden found that the 
SZ patients with SUDs often have worse psychotic symptoms, more nonadherence to SZ 
treatment, more drug-to-substance interactions, more medical comorbidities, increased violence, 
and increased suicides than the SZ patients without SUDs.11 This same study found that overall 
mortality was 2 times higher in the SZ patients with co-occurring SUDs than those without 
SUDs. More specifically, this study found that multiple SUDs were associated with the highest 
risks for poor outcomes in both countries. The ACCESS II study defined recovery for SZ 
patients as, “combined symptomatic and functional remission over at least 2 years at a 4-year 
endpoint.”8 Their results indicated that co-occurring SUD among SZ patients halve their chances 
at recovery. This study also found that from their sample of 187 SZ patients, the average number 
of SUDs per patient was 2.96.8  
A study which utilized an electronic health record found that the life expectancy for 
patients with psychotic disorders with a documented SUD was 63.1 years for men and 63.4 years 
for women, while the life expectancy for patients with psychotic disorders without a documented 
SUD was 65.1 years for men and 69.8 years for women.22 Additionally, this study found that 
patients with a documented SUD were 18.5% more likely to die from unnatural causes (accident, 
suicide, homicide) compared to those without a documented SUD. While this study showed that 
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SUDs decrease life-expectancy across the board for patients with psychotic disorders, it found 
that women were more affected than men by SUDs in regards to decreased life expectancy years. 
Interestingly, not all of the literature reviewed for this research reported worse outcomes 
in this population across all outcome domains when compared to SZ patients without SUDs. One 
study focused on the relationship between cannabis use and cognitive function in patients with 
first-episode schizophrenia spectrum disorder (FES). The study was interested in this relationship 
because previous studies have established the involvement of the dopaminergic system in 
cognition13 and its dysregulation in schizophrenia.14 The presumption was that THC would 
adversely impact neurocognitive functioning in FES patients with a history of cannabis use when 
compared to FES patients without a history of cannabis use. The study divided patients into four 
different groups: FES with lifetime cannabis use (FESCANN, N=30), FES without lifetime 
cannabis use (FES, N=53), a healthy control with lifetime cannabis use (HCCANN, N=20), and 
a healthy control without lifetime cannabis use (HC, N=49). The study evaluated patients in six 
different cognitive domains: speed of processing (SPOP), flexibility and working memory 
(FLEX), visual memory (VISM), verbal learning and memory (VERBM), and abstraction and 
executive functions (ABSTR).15 The study found that the HC group performed higher in all 
cognitive domains when compared with the HCCANN group except for ABSTR. The study also 
found that the HCCANN group performed better in all domains when compared to both groups 
with FES. However, patients in the FESCANN group performed better than the FES group in all 
six cognitive domains (see Figure 1). These results were contrary to what the authors anticipated. 
The study’s discussion about why the FESCANN group performed better than the FES group 
included two theories. First, the authors theorized that FES patients with lifetime cannabis use 
have superior cognitive skills which are needed to procure their drugs.16 The concept is that FES 
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patients with lifetime cannabis use are at a higher level of cognitive functioning prior to their 
first episode of psychosis than the FES patients without a lifetime history of cannabis use. 
Secondarily, they discussed the cognitive vulnerability theory which suggests cannabis can 
induce cognitive changes that may cause psychosis but does not lead to neurocognitive 
impairment to the degree that an isolated SZ diagnosis does (or in this case, FES).17 This theory 
further suggests that cannabis causes a transient cognitive breakdown which allows for psychosis 
in subjects that are not otherwise cognitively vulnerable to develop SZ. Whereas, patients 
without lifetime cannabis use who develop SZ are more cognitively vulnerable due to their form 
of the disease being triggered by a comparatively elevated genetic etiology. The authors of this 
paper stated that the cognitive vulnerability theory was more promising in relation to their 
results. The authors also stated that their results do not provide sufficient information to claim 
that cannabis is neurocognitively protective in FES, but rather that their results align with other 
studies that have demonstrated a contradictory result of increased cognitive ability in SZ patients 
with concurrent cannabis use when compared to SZ patients without cannabis use.17 
Theories About Overlap  
Research has produced substantial data about the prevalence of SUDs in SZ patients 
being greater than that of the general population. However, theories differ as to why the DD 
overlap is heightened in this patient population. One study in Denmark examined cannabis-
induced psychosis over time compared to the development of co-occurring SZ and cannabis use. 
This study focused its aim on cannabis-induced psychosis because, “previous research has shown 
cannabis-induced psychosis is a strong risk factor for later development of schizophrenia.”19 This 
research mentions that people with cannabis-induced psychosis have more than a 40% risk of 
developing SZ.19 Interestingly, this study found that cannabis-induced psychosis has steadily 
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increased from 2.8 per 100,000 person years in 2006 to 6.9 per 100,000 person years in 2014.19 
This increase in incidence of cannabis-induced psychosis was accompanied by an increase in 
incidence of SZ and cannabis use disorder (see Figure 2). This figure demonstrates the incidence 
of cannabis-induced psychosis in Denmark rose from roughly 3/100,000 person years in 1995 to 
6/100,000 person years in 2011 and to nearly 7/100,000 person years in 2014. Simultaneously, 
SZ and cannabis use disorder in Denmark rose from <1/100,000 person years in 1995 to nearly 
2.5/100,000 person years in 2011. This increase may not appear like a significant change at first 
glance, but when we consider SZ as a disease has an estimated global prevalence of 0.5-1%, this 
bump of more than 1.5/100,000 person years over 15 years is noteworthy. This increase in 
cannabis-induced psychosis paralleled an increase in THC concentrations in cannabis across 
Europe from 13% in 2006 to 30% in 2016.19 The authors attribute this increase in incidence of 
cannabis-induced psychosis and SZ to the paralleled rise in THC concentrations. 
A different study identified a Swedish nation-wide cohort of 2,494 with a first-time 
hospitalization for psychosis between ages 16-25.20 They analyzed the 5 years prior to and 5 
years following hospitalizations for psychosis. They found that the incidence of SUD 
hospitalizations increased each year leading up to the first-time hospitalization for psychosis and 
decreased each year following this index hospitalization (see Figure 3). This study concluded 
that SUDs likely contribute to psychotic disorder onset in many first-time hospitalizations for 
psychosis and that there is a window of opportunity following first-time hospitalization for 
psychosis when SUDs can be more predictably targeted for treatment.20 
Neurological Studies Analyzing Overlap  
A systematic review of 33 papers found that there was a general consensus that patients 
with co-occurring SZ and SUD had more brain affectations on structural and functional 
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neuroimaging studies than the isolated SZ groups. Specific brain alterations included volume 
deficits in cerebellar hemispheres, pons, thalamus, decreased grey matter in the anterior cingulate 
cortex, and shape abnormalities in the hippocampus and thalamus.18 However, this same review 
of 33 papers also found that SSD patients with co-occurring SUDs were less cognitively and 
emotionally impaired than SZ patients without SUDs.18 
A separate systematic review which attempted to review all existing neuroimaging 
studies in the SZ-SUD comorbid population found 43 studies to analyze. Two major limitations 
to this study were inconsistencies across the studies and the sample sizes which in most cases 
were 8-25 subjects. This analysis found that SZ patients in general have reduced grey matter in 
the cingulate cortex, dorsolateral prefrontal and frontotemporal cortex, limbic structures, and 
basal ganglia.21 They were able to find a correlation between the amount of grey matter reduction 
and duration of SZ illness and severity of SUD. One unique neurocognitive impairment found 
among the comorbid SZ and SUD group was increased impulsivity compared to the isolated SZ 
group. They also found that in the beginning of SZ disease, DD patients had less brain changes 
and improved cognitive functioning than the isolated SZ patients. They suggest that this may 
indicate a, “lower preexisting neuropathological burden” among subjects with co-occurring SUD 
than those exclusively with SZ.21 
An additional neurological study investigated a particular brain receptor’s activity that is 
known to be implicated in subjects vulnerable to the inheritance pattern of SZ.22 They carried this 
study out in mice. The N-methyl-D-aspartate (NMDAR) receptor has been independently 
implicated in both SZ and SUD. The study focused on the serine racemase (SR) gene which is a 
commonly accepted gene associated with SZ. Serine is a co-agonist of NMDAR receptors.22 
They found that mice with a silenced SR genotype (SR -/-) had impaired NMDAR receptor 
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function and a decreased sensitivity to the effects of cocaine on the behavior of the mice22 (see 
Figure 4). When applied to humans the principal takeaway is, “NMDAR hypofunction due to 
mutations in SR or other genes impacting glutamatergic function in SZ may render abused 
substances less potent and effective, thus requiring higher doses to achieve a hedonic response, 
resulting in elevated drug exposure and increased dependence and addiction.”22 This conclusion 
was reached based on the result that the intracranial self-stimulation (ICSS, T0) threshold was 
decreased in a dose-dependent fashion when mice were administered increasingly larger doses of 
cocaine in the wild-type (WT) SR +/+ mice but not in the SR -/- genotype mice. SR -/- genotype 
is characteristic of subjects vulnerable to the inheritance of SZ. 
Part 2 Literature Review: Evidence Based Medicine 
Antipsychotic (AP) medications are the mainstay of therapy for SZ patients and often a 
component of treatment in co-morbid SUD. Antipsychotic medications are largely classified as 
typical, or first-generation antipsychotics (FGAs), and atypical, or second-generation 
antipsychotics (SGAs).23 Today, most of the market share is comprised of SGAs and these are 
the antipsychotics most commonly used in patients with comorbid SZ and SUD. It is important 
to note at the outset of a literature review about AP medications utilized in DD patients that there 
is not a clinically unanimous first-, second-, and third-line treatment for this patient population. 
Nor, in the treatment of SZ patients without SUDs are there unanimous first-, second-, and third-
line treatments. AP medications are complex in that they have a variety of side effects. A large 
degree of patient-centered consideration must be takin into account when selecting an 
appropriate AP medication. 
Antipsychotic Medication Overview 
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A systematic review and meta-analysis of direct head-to-head comparisons of SGAs 
which consisted of 59 studies and over 45,000 subjects showed, “no consistent superiority of any 
single antipsychotic across multiple outcome domains.”24 That is not to say antipsychotic 
medications are ineffective in treating the DD patient population under study. Rather, it is to 
underscore that this patient population has complex needs and the therapeutic management calls 
for a more nuanced treatment approach. However, regarding all cause discontinuation of 
antipsychotic medication, clozapine and olanzapine were shown to be superior to several other 
SGAs.24 Antipsychotics are notorious for their side effect profiles. In general, FGAs have a 
higher rate of extrapyramidal side effects (EPS) than SGAs including akathisia, parkinsonism, 
dystonia, and tardive dyskinesia. SGAs display a metabolic and anticholinergic side effect profile 
including weight gain, glucose abnormalities, hyperlipidemia, sedation, orthostatic hypotension, 
and blood dyscrasias.23 SGAs have been shown to have specific profiles when broken down by 
unique side effect. For example, the meta-analysis of SGAs previously mentioned was able to 
show that olanzapine had more weight gain than other non-clozapine SGAs, while ziprasidone 
had less weight gain than other SGAs.24 Additionally, while clozapine was shown to be superior 
to other SGAs in regards to all-cause discontinuation it also had greater sedation and somnolence 
than other SGAs.24 When AP medication is prescribed for DD patients with SZ and SUD, special 
attention must be given to the intersection between medication efficacy and tolerability. This is 
because an intolerable but efficacious medication is not useful for patients. Other important 
considerations for SGAs include the following: SGAs have an FDA black-box-warning for 
increased mortality when used in the elderly with dementia. SGAs require comprehensive 
monitoring of patient weight, waist circumference, blood pressure, fasting plasma glucose, 
fasting lipid profile, and personal and family history for comorbid metabolic conditions. And 
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clozapine requires on-going blood work due to a possible life-threating side effect of 
agranulocytosis which is seen in 1-2% of patients who take clozapine for more than 1 year.25 
Long-acting Injectable Antipsychotics 
Medication non-adherence is a common issue among DD SZ and SUD patients. 
Medication non-adherence is associated with symptomatic relapses and poorer outcomes in SZ. 
Non-adherence may be attributable to several factors: lack of social support, lack of resources to 
afford medication, undesirable side effect profile of an antipsychotic medication, anosognosia 
(lack of patient understanding and perception of their disease), and disorganized thoughts 
inherent to the SZ illness which can result in forgetfulness and missed doses. Long-acting 
injectable antipsychotics (LAI-AP) are available as both FGAs and SGAs and can be delivered 
as once-monthly doses subcutaneously or intramuscularly which eliminates the need for patients 
to take a daily oral antipsychotic medication (OAP). A multicenter observational study with a 
sample of 40 patients with co-morbid SZ and SUD provided 6 months of LAI-aripiprazole 
(SGA) at a dose of 400mg every 4 weeks.26 Following the 6 months of therapy this observational 
study demonstrated that 77.5% of the patients who received LAI-aripiprazole had significant 
improvements in psychopathological symptoms. In terms of SUDs, cocaine use was stopped in 5 
out of 9 patients with cocaine use disorder and alcohol use was stopped in 3 out of 16 patients 
with alcohol use disorder.26 This study’s results show that 20% of 40 DD SZ and SUD patients 
were able to stop using a substance following 6 months of LAI-aripiprazole.  
A 3-year prospective and retrospective study compared the effectiveness of LAI-AP to 
OAP medication in 237 patients with comorbid first episode of psychosis (FEP) and SUD 
hospitalizations in Montreal.27 Despite presenting with poorer prognostic features such as 
homelessness, the LAI-AP group had a lower relapse rate than the OAP group (67.7% vs. 
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76.7%), a higher relapse-free survival time (694 vs 447 days), and an increased hospitalization 
free survival time (813 vs 619 days) (see Figure 5). This study concluded that LAI-AP should be 
considered a first-line treatment for FEP-SUD patients because of the decreased risk for relapse 
and rehospitalization even among individuals with poorer prognostic factors such as 
homelessness. 
A chart review of 1088 patients from a state psychiatric hospital in Oregon identified 
2031 discharges associated with antipsychotic agents and 1258 readmissions.28 The patients who 
received LAI-AP medications were associated with a decreased readmission rate at 1, 3, and 5 
years. At 1-year the patients who had received LAI-AP medication had a 15% decrease in 
hospital readmission compared to OAP monotherapy (excluding clozapine) (see Table 2). A 
similar study of SZ patients in a jail or prison setting comparing inmate recidivism rates between 
those receiving LAI-AP medication versus OAP medication would be of great benefit to those 
researching and working clinically with this patient population. Unfortunately, no such study was 
discovered during the literature review. 
An 18-month retrospective study assessed the association between at least 12 months of 
inpatient LAI-risperidone use and cost-effectiveness. The mirror-image study collected data on 
119 patients with SZ or schizoaffective disorder who had been switched to LAI-risperidone and 
the authors analyzed the difference in days of inpatient care as well as overall drug and 
institutional-care costs. They then compared these results with an equivalent time period in the 
same 119 patients prior to being switched to LAI-risperidone.29 This study took place in 
Germany and the conclusion was that after 12 and 18 months the LAI-risperidone treatment 
group had a mean reduction in days of inpatient care of 27.4 and 38.4 days.29 Additionally, the 
savings in drug and institutional-care costs were 21.1 and 21.9% (see Table 3). 
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If LAI-AP medications reduce patient non-adherence, can reduce the mean number of 
days of inpatient care, and increase drug and institutional-care cost savings then what barriers are 
preventing them from being used in a more widespread manner among the DD population of SZ 
and SUD? A two-part qualitative study was performed in Canada that analyzed both patient and 
physician perspectives regarding experience and perception of LAI-AP medications.30,31 In part-
one of this study,30 a focus group of 34 patients with SSD from across four Canadian provinces 
was gathered and qualitative evidence about patient perspectives on LAI-AP medication was 
produced. Their results showed that one patient with no prior experience of LAIs perceived a 
disadvantage as, “it is mostly for noncompliant people, therefore [it] is like a punishment” (see 
Figure 6). In part-two of this study,31 a focus group of 24 psychiatrists from across four Canadian 
provinces was gathered and qualitative evidence about physician perspectives on LAI-AP 
medication was produced. Their results indicate that the vast majority of psychiatrists prescribe 
OAP medication and that very few prescribe LAI-AP. From the focus group of 24 psychiatrists 
16 said they prescribe OAPs most or all of the time, 6 said they prescribe it often or frequently; 
while only 1 said they prescribe LAIs most or all of the time and 12 said they prescribe LAIs 
rarely31 (see Figure 7). The four themes that emerged from the psychiatrists were: there is limited 
knowledge about and experience with LAIs, there are perceptions that patients regard LAIs 
negatively, LAIs are often viewed as a final option for non-adherent patients, and there are issues 
around cost and storage of the LAIs.31  
A cost comparison from 2017 reported the cost of LAI-risperidone in Canada from $78 
for a 12.5mg vial to $326 for a 50mg vial (equating to an annual cost of $4,254-$8,508).32 This 
compares to the annual cost of the oral generic risperidone in Canada which is $443-$665.32 
There is a stark difference in recent prices for SGAs when comparing the oral and LAI 
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formulations. Interestingly, as noted in Table 3 from the study done in Germany the cost of LAI-
AP medication was greater than that of OAP medication, but the overall costs in the LAI-AP 
group was reduced due to a mean reduction in days of inpatient care.31 In the United States, the 
same 12.5mg vial costs $287 while the 50mg vial costs $1,122. These numbers are in even 
starker contrast to the $1.56/mg oral risperidone tablets.33 It requires no stretch of the 
imagination to realize that, particularly in the United States healthcare system, LAI-AP 
medications are cost-prohibitive for patients who are underinsured or uninsured with a serious 
mental illness like SZ.  
Clozapine 
Clozapine is an SGA that has FDA approval for treatment resistant SZ treated with other 
antipsychotics (TRS), persistent suicidal or self-injurious behavior associated with SZ, or EPS 
(particularly tardive dyskinesia) associated with SZ that has been treated with antipsychotics.34 A 
random-effects meta-analysis of all RCTs of antipsychotic drug trials in comorbid SZ and SUD 
patients was performed using multiple databases in USA, South Africa, Iran, Germany, 
Netherlands, and Western Europe. It went on to identify 19 RCTs published from 1999 to 2017 
with 1742 subjects. The following 8 antipsychotics were studied by the various RCTs: 
olanzapine, risperidone, haloperidol, clozapine, ziprasidone, aripiprazole, perphenazine, and 
quetiapine.35 The following outcomes were assessed in the meta-analysis: primary (reduction of 
substance users) and secondary (craving reduction, reduction of mean substance used, overall 
changes in positive and negative SZ symptoms). The main takeaways from this study were that 
no AP was proven superior to another in terms of reduction of number of subjects with SUDs. 
However, the authors note, “concerning substance use related outcomes, we find superiority of 
clozapine compared to ‘any other antipsychotic’ in terms of mean cannabis use and of 
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risperidone compared to olanzapine in terms of craving for cannabis.”35 This study is the most 
comprehensive and up-to-date meta-analysis of AP drug effects in people with both SZ and 
SUDs. Most of the studies had small sample sizes and while the authors affirmed this meta-
analysis as an important step in individualizing treatment for a subgroup of SZ patients with 
comorbid SUD, they reiterated in their conclusion to the research community that there is a 
deficiency of research in this area.  
A narrative review titled, “How and when to use clozapine” discussed the 
underutilization of clozapine in the treatment of SZ. The review quoted a study from 2016 which 
sought to present consensus guidelines to define TRS and describes as many as one third of 
patients with SZ symptoms failing to respond to antipsychotics.36 The review describes the 
underutilization of clozapine as a great, “mismatch between efficacy and utilization in clinical 
practice.”36 This review reports that barriers to clinician prescription of clozapine are due to: 
prescribers’ attitudes towards patient-related factors such as the assumption that patients will 
refuse the drug due to mandatory ongoing blood tests, system-level factors such as patient access 
to transportation for mandatory blood work, and the absence of a widely distributed evaluation of 
which patients would be eligible candidates for clozapine.36 The review goes on to encourage the 
utilization of Treatment Response and Resistance In Psychosis (TRRIP) criteria when working 
up a patient for TRS (see Table 4). Although, not an FDA approved indication, the review points 
out, “In addition to TRS, clozapine is recommended for persistent hostility, suicidality, or 
substance abuse in schizophrenia. Although, eligibility for these indications is less 
operationalized than for TRS, clinicians should consider the use of clozapine when any of these 
complications requires active management.”36  
Comprehensive Care Management  
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Often patients with comorbid SZ and SUDs have social determinants of health that 
interfere with their ability to obtain medical care, consistently attend appointments and lab 
checks, and ultimately confound their ability to attain optimal health outcomes. A study done by 
a non-profit behavioral health managed care organization (BHMCO) in Pennsylvania offered a 
care management bridging strategy plus usual care to 1243 Medicaid-enrolled adults. The aim 
was to reduce psychiatric and SUD readmissions. The control group consisted of 481 individuals 
who received what the study defined as ‘usual care’. The care management bridging strategy 
(i.e., the intervention arm of the study) consisted of a 15–30-minute onsite interview with the 
patients face-to-face. The interview had eight topics: reasons for readmission, barriers to 
remaining in the community, strategies to address the barriers, plans for discharge, strategies for 
accessing and using medications, components and education on how to utilize a crisis plan, 
factors that might help the patient be safe, and needs the patient has during their readmission that 
might assist with transitioning back to the community.37 Usual care was defined as discharge 
planning with referrals to appropriate behavioral health services such as drug or alcohol 
rehabilitation or community-based services like recovery residences.37 Patients with psychiatric 
diagnoses, SUDs, and DDs were all included in the study. Readmission rates were 1.7 times 
higher for those with DDs than patients who exclusively had a psychiatric or SUD diagnosis.37 
The three statistically significant results were that patients who received the care management 
bridging strategy plus usual care were 3.66% less likely to have an SUD-related readmission 
within 30 days, 6.29% more likely to follow-up with the planned rehab/recovery 
residence/outpatient SUD service within 7 days, and 6.99% more likely to follow-up with the 
aforementioned services within 30 days (see Table 5). The group of patients who received the 
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BHMCO bridging strategy were more likely to utilize follow-up SUD services and were less 
likely to have an SUD readmission within the next 30 days.37   
Part 3 Literature Review: Criminal Justice System 
The United States has the highest incarceration rate in the world and compounding the 
significance of this statistic is that people with mental illness are disproportionately represented 
in jails and prisons in the U.S. at an estimated rate of 2-4 times greater than the general 
population.38 As of 2017, this equated to there being 10 times as many people in prisons and jails 
with serious mental illness (SMI) than there were in state mental hospitals.38 There are historical, 
social, socioeconomic, and public health factors that explain this overcrowding of our country’s 
jails and prisons with patients who suffer from SMI.  
Prevalence Rates of Mental Illness and SUDs in a State Prison 
One study examined the extent and nuances of mental illness in Iowa state prisons. It 
utilized the Iowa Corrections Offender Network (the state’s prison data system) in order to 
quantify how many inmates had mental illness and SUDs.38 Out of a sample of 8,754 inmates 
2,453 (28.6%) had an SMI, 2,240 (26.1%) had an SUD, and 254 (3%) had a SZ diagnosis (see 
Table 6). According to the National Alliance on Mental Illness (NAMI) and the Substance Abuse 
and Mental Health Services Administration (SAMSHA) these rates compare to the general U.S. 
population as follows: SMI (5.2%, 2019), SUD (6%, 2017), and SZ (0.25-0.64%, 2019).39,40 This 
study concludes that the high rate of mental illness among inmates is in part due to inadequate 
access to mental health services in the community and that the high rate of SUDs among inmates 
is in part due to the “War on Drugs” political initiative led by the U.S. in the early 1970’s.38 
Co-occurring Mental Illness and Substance Abuse in Cook County in the 1980s 
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A more dated study published in 1991 assessed DD disorders among jail detainees in the 
Cook County Department of Corrections in Chicago. They found that persons with co-occurring 
mental illness and substance abuse were especially prone to being arrested due to the lack of 
appropriate mental health facility placements.41 Their data showed that among 22 male detainees 
with SZ 59% had current alcohol abuse or dependence and 42% had drug abuse or dependence 
(see Table 7).41 In the 1980’s when this data was collected, there were programs which served 
persons with mental illness or SUDs, but the authors highlight that there were not many 
programs that served patients with co-occurring mental illness and SUDs. The authors believe 
this led to a criminalization of those with DDs as the sentiment of the time was such individuals, 
“are too ‘mad’ for substance abuse programs and too ‘bad’ to be treated in mental health 
facilities.”41 
Inmate Perspectives on Mental Health and SUDs as Social Determinants of Incarceration 
 A qualitative study with a sample of 31 adult participants incarcerated in Massachusetts 
state prisons examined how adverse experiences, mental health, and SUDs serve as social 
determinants of incarceration. The authors opened with background statements indicating that 
people with SMI account for 15% of men and 31% of women incarcerated in jails and that nearly 
50% of all individuals incarcerated in the U.S. have substance use problems before they are 
incarcerated.42 They divided the sample into two groups based on high (>/=4) and low (<4) 
Adverse Childhood Event (ACEs) scores. There were 19 participants in the high ACE group and 
11 participants in the low ACE group. Their data showed that 94.7% of the high ACE group had 
a mental health diagnosis compared to 54.5% of the low ACE group, 73.7% of the high ACE 
group had a SUD compared to 36.4% of the low ACE group, and 84.2% of the high ACE group 
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reported that they used substances to self-medicate compared to 27.3% of the low ACE group 
(see Table 8).42  
The aim of the paper was to show that a portion of incarcerations are due to 
interconnections between ACEs, mental health, and SUDs. The study utilized a framework 
which broke the social determinants of incarceration into four categories: society, community, 
interpersonal, and individual determinants. Trauma was described as the primary interpersonal 
determinant that caused social isolation, mental illness, and SUDs. One participant described 
their experience,  
“I was sober for many years, but [after my father died] I started using drugs for 3 or 4 
days…to try and avoid that pain that I was going through…[Because I was high at the time] 
everything happened so fast that I started doing stuff like robbing people, even though I had 
money. Which is weird right? But, I didn’t want to go home because I didn’t want my family to 
see me high like that. So, I started going around and robbing people to buy more drugs and keep 
going…but I’ve never committed a crime when I wasn’t high” (Participant G).42 
Social isolation was described as an individual social determinant of incarceration by 
leading to crimes in an attempt to either gain acceptance or drugs. Another participant describes 
their experience,  
“[The problem is] just trying to keep my connection with the people in my life. Because 
itʼs when I start isolating itʼs when I start feeling alone and I get depressed and then my anxiety 
starts running away with everything and I donʼt make the right decisions and then I lean toward 
drugs and as soon as I start doing drugs all else is off the table. I donʼt feel anything. I donʼt 
think about consequences. I just want to stay in that state of mind. So, then I do whatever I have 
to do to keep getting access to more drugs” (Participant H).42 
Finally, participants were asked what their thoughts were regarding strategies to interrupt 
the pathways to incarceration. Participant G again offers their thoughts,  
“People with drug issues should have priority to go into treatment, especially people that 
have shorter sentences…work with those people first, give them the help they need, so when 
they go out [they can] be a better person. [When I was in prison before] they never asked me 
about drug problems, but this time they did ask me…and theyʼve got some programs now, so 
they referred me. I even asked the judge for help [with my drug problem] and she said Iʼd get 
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help. What they are doing now is different…they realize there is an epidemic going on, that 
people are committing crimes not because they want to but because they need it to get the drugs 
and they canʼt control it…They should have even more programs that are even longer…and keep 
you learning the whole time.”42 
 
LAI-AP in Patients with SZ and Criminal Justice Encounters  
 A retrospective study looked at the risk ratio (RR) of SZ patients having an encounter 
with the criminal justice system when treated with LAI-AP compared to the same period prior to 
starting LAI-AP treatment.43 Those treated with once monthly paliperidone palmitate LAI had 
the lowest RR at 6 months, 1 year, and 2 years for encounters with the criminal justice system 
following LAI-AP treatment (see Table 9). Given that SZ patients often have poor AP 
medication adherence and that co-occurring SZ and SUD patients are historically more likely to 
have encounters with the criminal justice system, this study offers relevant data. When patients 
with SZ were treated with LAI-AP (specifically, paliperidone palmitate) they were less likely to 
have an encounter with the criminal justice system compared with their own record during an 
equivalent timeframe prior to starting the LAI-AP therapy.43 
Expert Interview with a Behavioral Health Services Director 
An expert interview was conducted on 07/23/2021 with Angie Newstrom, MS, LPCC.44 
Angie Newstrom is the Behavioral Health Services Director with a company called MEND 
Correctional Care© which offers comprehensive healthcare to patients in the criminal justice 
system in multiple counties in MN, WI, and IA. This interview was particularly helpful in 
gaining an expert opinion on the state of care for patients with concurrent SZ and SUDs in the 
criminal justice system. The interview consisted of three primary questions. The below format 
will consist of the question asked as an italicized header followed by a paraphrase of the 
interviewee’s responses.   
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What are some of the unique complications among this dual diagnosis patient population in the 
criminal justice system? 
[This dual diagnosis population is very prevalent in jails and prisons. It is common for this 
patient population to be released from prison or jail and to eventually stop taking their AP 
medications and wind up back in prison or jail. Even those patients who get placed with a 
community-based program outside of prison or jail are still at risk to go off of their medications. 
One of the most difficult things with this patient population is to convince them to take their 
medications.  
A couple of unique complications with this patient population in the CJS (criminal justice 
system) include a general lack of prior medical records and the legal requirements that must be 
met prior to forced medical intervention. Our company does not always get a comprehensive 
medical record for each patient in the CJS. If a patient exhibits recidivism, there may be a 
medical record on file. But for many patients we are not given a full record. What this means is it 
is more difficult to know what the etiology of the patient’s psychotic symptoms are on 
presentation. Are psychotic symptoms indicating a long-standing SZ diagnosis? Is this the early 
development of SZ? Is this substance induced psychosis? Is this a psychotic episode due to a 
patient going off of their AP medications? It is difficult to know when there is not a prior history. 
Additionally, there are certain requirements that must be met before medical professionals can 
require a psychotic patient to take their medications. These requirements consist of being able to 
show the patient is a danger to self, others, or that they cannot care for themselves. However, it is 
more difficult to prove that a patient meets these requirements in prison when all of their basic 
needs are met within the facility. It is easier to see that a patient’s basic necessities are unmet in 
the community. But in prison this can be harder to prove. For example, some inmates sleep for 
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many hours every day in prison in an attempt to try and sleep away their sentences. But SZ 
patients may be exhibiting negative symptoms such as flat affect or anhedonia and will lay in bed 
for hours on end due to their psychiatric illness. Or, if a patient is not vocalizing their thinking it 
is difficult to assess the disorganized nature of their thoughts or delusions. Sometimes writings 
can display disorganized thinking and be useful. In addition, these negative symptoms are more 
difficult to effectively treat with the AP medications. As a result, it is more difficult to link the 
negatives symptoms of SZ to a psychotic process in prison than it is in the community. And the 
downstream effect of this is that a patient often times must deteriorate to an uncomfortable level 
until clinicians can legally intervene and administer AP medication.] 
How are long-acting injectable antipsychotic medications utilized in the prisons and jails and 
how does this impact patient outcomes? 
[LAI-AP medications are sometimes used. Generally, if a patient comes in on an LAI-AP they 
will continue to get that medication. These patients generally seem to do better. There are fewer 
opportunities for missed or skipped doses. These LAI-AP medications keep the patient 
medicated longer and they decrease the chance that the patient will fail to follow through on 
taking their medication. Additionally, there is less need to try and convince the patient to take 
their medication.] 
What barriers interfere with this patient population from succeeding in the community after 
release from prison/jail? 
[There are a lot of issues. There is a lack of a supportive social networks for many of these 
patients. There is a lack of stable housing. Urban areas often have more community-based 
organizations, but rural areas do not have the same resources of interdisciplinarian mental health 
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teams. There is a lack of psychiatric beds which means patients in an acute psychotic episode go 
to the ED and can be held there for hours to days while clinicians look and wait for a crisis bed 
to become available at a mental health hospital. There is a general lack of resources for this 
patient population. There are not enough community health centers and there are not enough 
psychiatrists to provide adequate care to this patient population.] 
Methods 
 The vast majority of the articles obtained for this research were conducted through 
Augsburg University’s online Lindell Library Searches. This resource utilizes a wealth of 
databases for each search conducted. An advanced search option was utilized to narrow search 
results to peer reviewed articles published between 2019-2021 in order that at least 15 peer 
reviewed articles used for this research were published in the past 3 years. More than 20 of the 
articles utilized for this research were published in the past three years. Keywords used in the 
Lindell Library searches included: schizophrenia, substance use disorder, criminal justice 
system, antipsychotics, dual diagnosis, and severe mental illness. The abstracts were read in 
order to determine which articles were relevant to the research question being investigated. 
Those that were relevant were cited, downloaded, and returned to at a later time for a more 
thorough reading in order to learn what research on the topic has shown. Two textbooks required 
during the academic phase of the present Master of Science program were utilized in this 
research.1,5 One external e-textbook on the topic of dual diagnosis was utilized.3 One expert 
interview was conducted with a Behavioral Health Services Director who works with a 
correctional care group called MEND Correctional Care, PLLC. For the expert interview, 
questions were drafted and sent to the interviewee and a date was determined to conduct the 
interview via a Zoom online. 
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Discussion of Literature Review 
 The research conducted for this paper sought to answer the following question: among 
patients with a DD of SZ and SUD what current treatments provide optimal outcomes? It became 
apparent that the most beneficial direction of this research would include a 3-part literature 
review of studies showing overlap of SUD prevalence in SZ patients, studies demonstrating 
evidence-based medicine, and studies speaking to the unique dilemma that this patient 
population faces with the criminal justice system. This patient population has complex needs and 
it is appropriate that a multifactorial approach to treatment would offer the best results. As the 
literature review on this topic has been carried out it has become evident that there is no single 
treatment modality or pharmacotherapy that is superior to all others in all situations. With that 
said, the available research does show certain treatments as better than others in some situations. 
The research also indicates that a multi-disciplinarian, nuanced, patient-centered approach will 
be necessary to best help these patients with a DD of SZ and SUD. The discussion portion of this 
paper will include an analysis of the 3-parts of the literature review centered around what 
treatments are currently utilized in this patient population to offer optimal outcomes. 
 It was found that there is a prevalence rate range of SUD in SZ patients of 18.5-67.4%. 
While this range is wide, it does correlate roughly with one systematic review’s estimate of 18.5-
61.5% based on 26 studies. Said another way, based on the literature reviewed for this paper the 
18.5-67.4% co-occurring prevalence range was obtained by compiling the prevalence rates from 
several studies that obtained data on this topic. The prevalence range of 18.5-67.4% is an 
estimate of how many SZ patients will develop an SUD at some point in their lives (whether that 
be prior to, at the same time of, or subsequent to SZ diagnosis). Interestingly, nicotine is usually 
not included in the DD of SZ and SUD because it is not included in the DSM-V classification of 
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SUD. It has its own classification as tobacco use disorder. SZ patients as a population carry a 
prevalence of cigarette use between 60-90%.6 Nicotine use should be addressed in SZ patients, 
but it may not be the most important substance that needs to be addressed at the outset of 
treatment. It is important when addressing SUDs in any patient population, including SZ 
patients, to go slow and address one substance at a time if there are multiple substances being 
abused. The ACCESS II study reported that the average number of substances being used by the 
187 SZ patients was 2.96.8 This is significant because the more substances being used by a 
patient, generally, the worse their outcomes will be in terms of medical comorbidities, 
medication adherence, and substance to substance interactions. As clinicians, it is important to 
understand several changes at the same time can be overwhelming for a patient and lead to non-
adherence. With that said, nicotine can lower the concentrations of certain antipsychotics in the 
blood by as much as 50%, so it is still a relevant part of the work-up for a SZ patient.3 
Additionally, it is known that cigarette use is a strong risk factor for heart disease which could 
compound vascular disease progression in conjunction with SGA-induced metabolic 
comorbidities like obesity and diabetes. 
 As previously mentioned, the more substances being abused by a SZ patient the poorer 
their prognosis. As the ACCESS II study showed, the more substances abused the less likely a 
patient will successfully recover.8 This seems to align with some of the comments made by 
inmate participants in the qualitative study regarding ACEs, mental health, and SUDs as 
determinants of incarceration. One participant described not having any regard for the 
consequences of their actions when committing a crime in order to obtain their drug. They 
described it as if nothing else mattered when they were needing to get high, they just needed to 
maintain that state of mind. Patients are unable to think clearly when addicted to a substance. 
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When there are multiple drugs involved this effect may be intensified and a SZ patient who is 
already predisposed to disorganized thoughts and decreased cognitive ability independent of the 
effects of an addictive substance will not be able to make rational decisions in light of their well-
being. Three separate studies from the literature review called for public policy changes that 
would better assist DD SZ and SUD patients in order to avoid incarceration and be appropriately 
placed in facilities that can manage both psychiatric and SUDs.  
 It was noted in the literature review that outcomes for DD SZ and SUD patients were not 
unanimously worse when compared to an isolated SZ diagnosis. In some situations, the DD 
patients fared the same or better than SZ patients in tasks such as working memory, visual 
immediate recall, visual recognition, verbal recognition, metaphor processing, and degree of 
cognitive and emotional impairments.15,18,45 A range of theories exist in the research community 
about co-occurring SUDs in SZ patients. Some think that cannabis use disorder might be 
protective in SZ patients. Others think it is damaging. There is evidence that cannabis can induce 
psychosis in individuals with susceptible inheritance patterns for SZ. The stance of this present 
discussion is that patients with co-occurring SUDs that predate the SZ diagnosis (particularly 
cannabis use disorder) have a lessened degree of SZ pathology from the outset of the disease; not 
due to the effects of cannabis, but owing to the theory that these individuals possess a lessened 
degree of psychopathology than those with an isolated SZ diagnosis. Additionally, there exists 
some probability that if cannabis is shown to induce psychosis (a known risk factor for later 
development of SZ) that some SZ patients may not have developed the disease had their SUD 
been nonexistent in the first place. Also, SZ patients with co-occurring SUDs necessitate some 
level of social, cognitive, and emotional capacity in order to communicate with others to procure 
their drug. As previously mentioned, patients with a sole SZ diagnosis may have worse outcomes 
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in studies pertaining to working memory, visual immediate recall, visual recognition, verbal 
recognition, and metaphor processing owing to the theory that their cognitive ability has been 
more compromised due to their greater progression of organic mental illness than those with co-
occurring SUD. 
 The study done in Denmark that found a parallel between cannabis-induced psychosis 
and the increasing concentrations of THC in cannabis throughout Europe from 2006-201419 
offers interesting material for discussion. When thinking about the overlap between SUDs and 
SZ it is appropriate that we draw on data from studies with long time horizons. One retrospective 
study which observed co-occurring SUDs in SZ patients dates back to 1968.10 While we may be 
talking about the same psychiatric diagnosis of SZ, when it comes to SUDs, the cannabis has 
changed. The THC concentrations in the Denmark study rose from 13% in 2006 to 30% in 
2016.19 That is more than a 100% increase in THC concentration in one decade. The study 
mentioned that cannabis-induced psychosis is a strong risk factor for the later development of 
SZ. If this is the case, we might expect to see an increase in SZ diagnoses further in time as 
concentrations of THC in cannabis have increased dramatically in the early 2000’s. This is 
another important public policy issue to which the fields of psychiatry and addiction medicine 
could offer advice in regards to the legalization and regulation of cannabis. Certainly, there is an 
ethical dimension at play in the legalization of cannabis debate if there is a possibility that we as 
a global community are growing our SZ prevalence by allowing increasingly high THC levels in 
cannabis to be distributed and accessed. 
 SZ patients are known to have a variety of genetic aberrations that contribute to their 
psychiatric phenotype. The study which focused on the serine racemase (SR) gene and its 
silencing effects on NMDAR receptor activity provided interesting information about the 
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interplay between SZ and SUDs. While this study cannot be generalized to the entire SZ patient 
population owing to the study being conducted in mice, it does pose a helpful theory for 
discussion. The study’s main takeaway was that the mice with silenced SR -/- genotype were 
observed to have less of a hedonic response to cocaine than the wild type (WT) mice with SR 
+/+ genotype.22 The theory is that patients with SZ, who often have an implicated SR -/- 
genotype, are more prone to developing an SUD than persons with SR +/+ genotype because 
they require more of the substance to achieve the same effects.22 If this theory could be validated 
in other animal or human studies, it may suggest that SZ patients are more vulnerable to 
developing a SUD owing to their brain chemistry. The implication for SZ patients may be 
described as analogous to a substance abuser who has developed a degree of tolerance to a drug 
even before they have begun to use for the first time. 
 The largest meta-analysis ever conducted for OAP use in SZ patients was reviewed and 
suggested that olanzapine and clozapine showed some superiority to other SGAs in all cause 
discontinuation of AP medication in SZ.24 Although this study was comprehensive in terms of 
the available research to study OAP medications head-to-head, it did not produce clear 
guidelines on which AP medications are best to use in all situations for SZ patients. As 
mentioned in the literature review, AP medications have varied side effects with varied degrees 
if impact on different patients. The meta-analysis reinforces the sentiment that when prescribing 
AP medications in SZ clinicians must begin with the patient, their medical comorbidities, their 
goals for symptom reduction, and any previous history they have had with antipsychotics before 
initiating a medication. For example, if a patient with SZ has comorbid obesity the clinician 
should have a discussion with the patient and/or caregivers about a medication like olanzapine 
and tell them it has been shown to have more weight gain than ziprasidone. This ought to be 
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considered alongside the patient’s PCP who manages any present comorbidities. Or, if the 
patient has mild SZ symptoms and wants to avoid sedating or somnolent side effect profiles, the 
clinician should advise against quetiapine.   
 Multiple studies reviewed LAI-AP use in DD SZ and SUD patients. LAI-AP (specifically 
aripiprazole and paliperidone palmitate) did show better patient outcomes in terms of medication 
adherence, decreased psychotic relapse and hospitalizations over time, SZ symptoms, reduction 
in substances used in SUDs, and reduction in severity of dependence in SUDs.26,27,43 Medication 
adherence can be more difficult for SZ patients due to several factors previously mentioned. 
LAI-AP offers a good alternative to daily OAP in order to keep patients with SZ and SUD 
stabilized on a daily a basis. However, in order to qualify as a candidate for LAI-AP a patient 
must reside in a facility or home where dependable medical care can be offered or possess 
reliable transportation to commute monthly to a site where LAI-AP is offered. LAI-AP 
medication ought to at least be a consideration for all patients with DD SZ and SUD.  
 Discussion about which AP medications offer optimal outcomes is complicated by 
barriers that interfere with their utilization. Two separate studies from the literature review noted 
that the perspectives of psychiatrists about patient attitudes towards particular AP medications is 
one reason why certain options are underutilized. In the instance of clozapine, psychiatrists have 
said they avoid clozapine due to the belief that patients will refuse the medication owing to the 
necessary ongoing blood work associated with the treatment.36 In the instance of LAI-AP 
medications, some psychiatrists have said they do not use this mode of medication delivery due 
to the physician perception that patients view these injections with a negative attitude.31 While 
there may be merit to these perceptions about patient attitudes, it is important that clinicians 
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reframe particular medications that have shown superior outcomes in order that patients might 
approach the shared-decision making process from a fully informed position. 
 The study conducted in Oregon comparing LAI-AP to OAP medications showed an 
overall reduction in hospital readmissions of 15% for psychiatric patients who were discharged 
on LAI-AP when compared to those discharged on OAP medication (excluding clozapine).28 The 
German study comparing LAI-AP to OAP medications showed a reduction in drug and 
institutional-care costs of 21.1 and 21.9%29 respectively when patients were given LAI-AP 
medication instead of OAP medication. If there is reason to believe that LAI-AP medication 
offers better patient outcomes and potentially lower institutional costs, why are they not utilized 
more often? The literature reviewed indicated that the answer to this question lies in part with 
physician and patient attitudes towards LAI-AP medication and in part, with the financial burden 
associated with these LAI-AP medications (particularly in the context of the United States).  
The two-part qualitative study conducted in Canada indicated that from a sample of over 
20 psychiatrists very few ever prescribe LAI-AP medications. These Canadian psychiatrists 
listed unfamiliarity with LAIs as one reason for not prescribing them,31 as well as the perception 
that patients have a negative association with LAIs. The sample of over 30 patients with SSD 
cited one reason for not wanting LAIs as the perception that these medications are largely 
reserved for non-adherent patients for whom LAIs are the last treatment resort.30 One question 
worth posing based on analysis of the research is, do we have an element of circular reasoning 
going on here? Psychiatrists report that they think LAIs are best reserved for non-adherent 
inidividuals, so they tend to use them only in those situations. This behavior perpetuates the 
patient perception that LAIs are indeed a last resort for non-adherent patients and hence a 
punishment. Then, psychiatrists perceive those patients do not prefer LAIs so they avoid them 
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due to their perception of patients’ negative attitudes towards LAIs. If this dynamic is at play, the 
takeaway would be that it is important that clinicians consider the manner in which they frame a 
medical treatment approach when presenting it to a patient as an option.  
When comparing the cost of LAI-AP medications one quickly realizes that costs are not 
equal between countries. In Canada, where healthcare is funded by the government as a single 
payer, one 50mg vial of LAI-risperidone costs $326.32 In the U.S., the same vial of LAI-AP costs 
$1,122.32 This is more than three times the cost before accounting for differences in physician 
associated fees such as injecting the medication. Several factors are at play here preventing this 
population of patients from receiving LAI-AP medication as a viable treatment option on a more 
regular basis in the U.S.: the cost for the same LAI medication is much greater in the U.S. The 
U.S. healthcare system is in large part funded by multiple private payers who require monthly 
premium payments in exchange for health insurance. A disproportionate percent of DD patients 
with co-occurring SZ and SUD are detained as inmates in jails and prisons. And there are 
lingering attitudes among both psychiatrists and patients with SSD that LAI-AP medications are 
less desirable than OAP medications. These factors explain some of the barriers that are 
preventing this patient population from receiving LAI-AP medication more frequently in the 
U.S.  
 One of the articles reviewed discussed how and when to use clozapine in SZ patients.36 
While this medication does not currently have FDA approval to specifically treat DD SZ and 
SUD patients, it does have FDA approval for TRS. The article’s aim was to encourage the 
utilization of this medication as it has proven efficacious in TRS. It also noted that as many as 
1/3 of SZ cases are considered TRS and that a systematic approach to defining and diagnosing 
TRS is imperative so that patients receive the most adequate care currently available to them. 
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While clozapine is utilized by prescribers treating SZ, the article noted that there is not an equal 
distribution across treatment environments where this medication is utilized. Instead, there are a 
condensed number of prescribers who use the medication at a disproportionately high rate 
compared to other prescribers. Given the complexity of this medication’s side effects it would 
make sense that some prescribers are not comfortable or familiar enough with clozapine to 
prescribe it and instead refer their patients to the psychiatrists who do have. There is room for 
benefit in launching an initiative to familiarize PCPs, particularly those who see patients with SZ 
or SUD diagnoses, with the TRS consensus criteria produced by the Treatment Response and 
Resistance in Psychosis working group (see Table 2). The goal of such an initiative would be to 
better capture SZ patients who meet the qualifications for TRS and are candidates for treatment 
with clozapine.  
 An overarching theme of the literature review was that DD SZ and SUD patients have 
complex needs that must be met with a nuanced, interdisciplinarian approach. The study 
conducted by the BHMCO which implemented a bridging strategy for patients with psychotic 
and SUD related hospitalizations highlights the importance of such an approach. The 
intervention under investigation in this study consisted of an additional 15–30-minute interview 
with the patient conducted by a social worker prior to discharge. The results showed decreased 
rehospitalization for psychosis or SUD within 30 days as well as increased therapy adherence 
within both 7 and 30 days.37 In this particular hospital where the bridging strategy was studied 
this intervention provided better patient outcomes than usual care. These measures could be 
applied to other settings where the same resources exist. An analysis measuring the benefit-to-
cost ratio of such an intervention would be interesting to compare alongside the usual care. The 
author’s perspective is that the 15-30-minute interview in addition to the follow-up consulting 
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and documentation work time of a social worker would cost less than the corresponding 
increased rates of psychosis and SUD relapse within 30 days and decreased medical adherence 
within 7 and 30 days. Not only does this multidisciplinary intervention offer potentially better 
patient outcomes in the comorbid SZ and SUD population, but it could potentially cost less than 
not offering such an intervention. More research is needed to validate such a statement.  
 The disproportionate incarceration rates of DD SZ and SUD patients compared to the 
general population in the U.S. is an important issue with both societal and clinical implications 
for this patient population. One of the older articles reviewed for this research was published in 
1991 and included data from the 1980’s. In this paper, the authors described police being in a 
difficult position when it came to adequately connecting DD SZ and SUD patients with the 
appropriate services. They stated that many facilities would turn away such individuals because 
they fell into a ‘grey’ area not fitting strictly into a category as either a SZ patient or a SUD 
patient. An example situation portrayed in the paper was that of a police officer picking up an 
individual for illicit substance use who had a documented comorbid SZ diagnosis. The officer 
would attempt to bring this individual to multiple behavioral health or drug rehabilitation 
facilities, and when unable to find a facility willing to accept the individual, the individual would 
be held in a jail or prison until adequate services could be found.4 The article did not speak to the 
length nor brevity of the holding-times that these patients experienced. Additionally, based on 
the largest general population survey at the time (Epidemiologic Catchment Area Project, 1990) 
this study found that detainees with SZ had much higher rates of lifetime alcohol use disorder 
(84.9%) and lifetime drug use disorder (60.9%) when compared to the general population (33% 
and 27.5% respectively).4 This was and still is a significant finding because it could support the 
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suggestion that not having adequate treatment facilities for DD SZ and SUD patients is 
consequently increasing the prevalence rate of SUDs among SZ patients.  
 One of the studies utilized the Iowa state prison’s data system to collect information on 
inmates. They found that out of a sample of 8,754 inmates 28.6% had SMI, 26.1% had an SUD, 
and 3% had a SZ diagnosis.38 These rates are respectiely 5, 4, and at least 4 times greater than the 
rates in the general U.S. population as reported by the NAMI in 2017 and SAMHSA in 2019 
(SMI, 5.2%; SUD, 6%; SZ, 0.25-0.64%).39,40 Admittedly, more demographic information would 
need to be compared prior to generalizing the results from inmates in Iowa state prisons to that of 
the general U.S. population. However, these comparisons are staggering when we consider the 
population under study are people with SZ and a comorbid SUD. These are issues we must sit 
with as a society and recognize that we are detaining and treating many of our most severely 
mentally ill individuals in prisons and jails. 
 LAI-AP medication use in patients with SZ and SUD within the setting of jails and 
prisons was searched for during the literature review. One study did indicate LAI-AP medication 
reduced the amount of criminal justice encounters among SZ patients.43 However, no study was 
able to be identified that looked at the recidivism rates among inmates with co-occurring SZ and 
SUD who are released into the community with an LAI-AP regimen versus recidivism rates 
associated with OAP medication. This would be an interesting study to locate and or perform. 
 The qualitative study which acquired perspectives from inmates about the role that ACEs, 
mental health, and SUDs play as social determinants of incarceration offers valuable insight from 
those who have first-hand experience with mental illness, SUD, and incarceration. One inmate 
mentioned that at a previous sentencing he was not asked about anything related to SUDs 
(though he was using a substance at the time).42 He said how things had changed at the time of 
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the interview, and that he was engaged about this topic during his more recent sentencing.42 This 
inmate interview highlights how some of the conditions have changed in jails and prisons in 
terms of providing care for inmates with SMI and SUDs. The author’s conviction is that jails and 
prisons are not the ideal place to treat individuals with DDs of SZ and SUD. However, it is a 
massive endeavor to translocate these individuals to appropriate facilities that do not exist in 
adequate numbers today. Until appropriate solutions are provided outside of jails and prisons, the 
developments highlighted by the inmate from the qualitative study are important to recognize, 
replicate, and distribute across all incarceration settings where DD patients with SZ and SUDs 
are being detained. 
Conclusion 
 This research paper endeavored to answer the following question: among patients with a 
DD of SZ and SUD what current treatments provide optimal outcomes? In reviewing the 
literature for this patient population, it became apparent that there is a significant co-occurrence 
rate of SUD in SZ patients, there are a variety of pharmaceutical and non-pharmaceutical 
therapies that have shown improvements in patient outcomes, and a significant impediment to 
this patient population’s recovery and remission from psychopathology is the criminal justice 
system in the United States.  
 Based on the results from this research which includes a systematic review of more than 
25 articles published on the topic from 1990-2015, the prevalence rate of co-occurring SUD in 
SZ patients was estimated to be between 18.5-67.4%.7,8,9 This range is lower than the 47-70% 
range quoted in a chapter of a textbook written for clinicians about the topic of dual diagnosis of 
SUD in SZ patients.3 This significant co-occurrence rate of SUD is much greater in SZ patients 
than the general population. The overlapping of SUD in SZ complicates patient outcomes and 
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has been worse outcomes including increased psychotic symptoms, more medication 
nonadherence, more drug-to-substance interactions, more medical comorbidities, increased 
violence, and increased.11 It is important for clinicians to be aware of this high prevalence rate of 
SUD among SZ patients. It is especially important for beginning treatment as soon as possible 
because time is of the essence when attempting to optimize patient outcomes in SPMI. 
 Current EBM shows that AP medication is the mainstay of pharmacotherapy in this 
patient population in conjunction with a comprehensive care approach which includes 
connecting these patients with adequate mental health resources. Clozapine has been shown to be 
superior by a meta-analysis of 19 RCTs for treating SZ patients with co-occurring cannabis 
use.35 Additionally, the authors of a narrative review titled, “How and when to use clozapine,” 
recommend that it be used in co-occurring substance abuse in SZ.36 LAI-AP medication has 
shown improved outcomes in terms of patient adherence, decreased psychotic symptoms,26 
decreased hospital readmissions,28 decreased institutional costs (in Germany),29 and even 
decreased substance use in co-occurring SZ and SUD.26 Unfortunately, there are barriers to 
widespread utilization of LAI-AP medication. Many psychiatrists and patients have negative 
perceptions of LAI-AP medication,30,31 and there is a large cost-discrepancy between LAI-AP 
versus OAP medication.32,33 This cost discrepancy is most poignant in the United States, 
regrettably the country with the highest incarceration rate in the world.38  
 Patients with co-occurring SZ and SUD have historically been criminalized by society in 
part due to the fact that there has been inadequate services and facilities for patients with 
overlapping SMI and SUDs.41 Patients with SMI and SUDs are disproportionately represented in 
U.S. jails and prisons.38 Inmates with SMI and SUD have themselves said that U.S. prisons and 
jails need more programs targeted at treating inmates [particularly those with short sentences] for 
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their substance abuse.42 LAI-AP medication used over 6 months has reduced the risk ratio of SZ 
patients having criminal justice encounters when compared with an equivalent time period for 
the same patients prior to LAI-AP use.43 LAI-AP medication ought to be a consideration for 
patients with a history of criminal justice encounters. Given the fact that as a society we lack the 
necessary infrastructure to translocate the number of inmates with SPMI and SUD to settings 
where they might be more appropriately treated, the consideration of LAI-AP should be made a 
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